Navigation Links
Diamyd(R) Study Published in Prestigious New England Journal of Medicine
Date:10/9/2008

results are considered to be of such quality and clinical value strengthens our position in the medical and industrial worlds," says Elisabeth Lindner, president and CEO of Diamyd. "We are now moving forward preparing the market introduction of Diamyd(R)."

About the article:

"GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes"

J Ludvigsson et al., N Engl J Med 2008;359 (Epub ahead of print 10.1056/NEJMoa0804328)

About Diamyd(R) Type 1:

Diamyd(R) Type 1 is the treatment of recently diagnosed patients with the Diamyd(R) diabetes vaccine. Diamyd(R) Type 1 is a simple treatment without any serious side effects. This treatment is now being tested in Phase III studies in Europe and the US. The company plans to complete the application for market approval in late 2010. The annual market for Diamyd(R) Type 1 is estimated at about one billion dollars.

About the mechanism of action:

Type 1 diabetes is an autoimmune disease in which the body's own immune system attacks the cells in the body that produce insulin. The active ingredient in Diamyd(R) is glutamic acid decarboxylase (GAD), which is a dominant antigen in type 1 diabetes. By treating with GAD formulated as a vaccine, the patient's immune system is affected in such a way that it down regulates the attack on the insulin-producing cells. Stopping this autoimmune process is the cornerstone in curing type 1 diabetes.

Immunological analyses from the Phase II study as presented in the New England Journal of Medicine help to form an understanding of the Diamyd(R) vaccine's mechanism of action. A significant increase in regulatory T-cell activity was seen, which is considered decisive in counteracting the course of autoimmune diseases.

About the Phase II study:

The Phase II study now being presented comprised 70 patients aged 10-18 with type 1 diabetes. The patients, who received two injections of Diamyd(R), retained their own ability to pro
'/>"/>

SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
2. Wild Blueberries Take Top Spot in New Antioxidant Research Study
3. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
4. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
5. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
6. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
7. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
8. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
10. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
11. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... in two healthcare conferences during the third quarter, the ... Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation will ... details on each event are below: , ... 2014 in Boston , MA.  The ...
(Date:7/29/2014)... -- Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today reported net income for the quarter ended June ... and non-GAAP net income of $94.0 million, or $0.88 per ... earlier was $93.3 million, or $0.81 per diluted share, and ... share.  Net sales for the quarter ended ...
(Date:7/29/2014)... -- New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... The study finds that the majority of ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
(Date:7/30/2014)... Bridgeport, Connecticut (PRWEB) July 30, 2014 ... released a new magnetic sports bracelet for pain relief ... 100 times strength carbonized titanium embedded in a silicone ... titanium. It also has Germanium and is embedded with ... magnetic balance bracelet. , “Pain Free Living has 12 ...
(Date:7/29/2014)... 30, 2014 VisitandCare.com today ... been added to the company’s exclusive network to help ... of joint efforts — as top fertility clinics in ... offer affordable, state-of-the-art, and successful IVF treatments. , The ... a comprehensive study by professionals at VisitandCare.com. The goal ...
(Date:7/29/2014)... MO (PRWEB) July 30, 2014 ... have recently been awarded the Patient-Centered Medical Home ... the National Committee for Quality Assurance. Only one ... NCQA Level I, Level 2, or Level 3 ... participate in Patient-Centered Medical Home report faster access ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical ... I trial with DS107G, an oral formulation of Dihomo ... randomized, placebo-controlled, double-blind, single-ascending and multiple dose Phase I ... of food on DS107G in healthy subjects. , ... following both single and multiple oral doses over 28 ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates ... as all other disturbing symptoms that hemorrhoids commonly causes. ... researcher and natural medicine expert. , The author ... to the elimination of symptoms such as itching, burning, ... Learn more about the H Miracle by visiting the ...
Breaking Medicine News(10 mins):Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
... for growth hormone therapy’s anti-aging powers – says a team ... papers based on growth hormone.// ,'There is certainly ... to an otherwise healthy person will make him or her ... potential for adverse side effects.' - says Dr. Hau Liu, ...
... a member of a large family may not be best ... greatly influenced the development of stomach cancer linked to the ... to be especially vulnerable to the most common type of ... the records of more than 7,000 Japanese-American men who were ...
... have reported an interesting find: statins, or drugs used ... actually have an added benefit; //reduce the chance of ... Australians use pop statins, which are lipid-modifying drugs that ... drug for reducing cholesterol levels. , The drug ...
... ideal world, the answer is no, as breast milk ... ,However, in the same developing countries where the ... is often considered the only safe and nutritious food ... research is needed. ,A new study conducted ...
... true; for fat people and inventors. ,Scientists have always ... Britain are no exception. //Currently, two thirds of the population can ... to put a morbidly obese figure of 2.2 million pounds ... London. ,Bloom’s quest is to create a chewing gum or ...
... chicken eggs that can be used to produce drugs like those ... at Edinburgh, Scotland have claimed to create a flock ... to create life saving drugs. ,These drugs could ... National Health Service incurs, according to them. , For ...
Cached Medicine News:Health News:Is Growth Hormone – a Key to Longevity 2Health News:Link Between Family Size and Stomach Cancer Found 2Health News:Link Between Family Size and Stomach Cancer Found 3Health News:Chew That Fat Away 2Health News:No Pills Just Omelets 2
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... Inhibins are heterodimeric proteins that suppress the ... the pituitary. Inhibin consists of two distinct ... together. Inhibin A consists of the alpha-subunit ... alpha-subunit and betaB-subunit. Only the dimeric forms ...
... II (IGF-II) is a 7.5 kDa peptide which ... postulated to have mitogenic and metabolic actions involved ... mediated by binding to target cell receptors. IGF-II ... IGF receptor, a monomeric protein which also serves ...
... A (PAPP-A) is a large placenta-derived ... high concentrations by placental trophoblast cells, ... circulation in increasing concentrations throughout gestation ... specific to pregnancy since measurable levels ...
Medicine Products: